XML 14 R3.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 28, 2025
Sep. 29, 2024
Sep. 28, 2025
Sep. 29, 2024
Statement of Comprehensive Income [Abstract]        
Net income before allocation to noncontrolling interests $ 3,550 $ 4,473 $ 9,452 $ 7,644
Foreign currency translation adjustments, net 365 131 (66) 200
Unrealized holding gains/(losses) on derivative financial instruments, net (1) (303) (396) 41
Reclassification adjustments for (gains)/losses included in net income [1] 177 (175) (242) (334)
Other comprehensive income, cash flow hedge, gain (loss), before tax, total 176 (477) (638) (293)
Unrealized holding gains/(losses) on available-for-sale securities, net (10) 59 124 (17)
Reclassification adjustments for (gains)/losses included in net income [2] (97) (6) (25) 80
Other comprehensive income (loss), available-for-sale securities, before tax, total (107) 54 100 63
Reclassification adjustments related to amortization of prior service costs and other, net (16) (27) (70) (83)
Reclassification adjustments related to curtailments of prior service costs and other, net (5) (2) (49) (2)
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service costs and other, before tax (21) (29) (119) (85)
Other comprehensive income/(loss), before tax 413 (322) (723) (115)
Tax provision/(benefit) on other comprehensive income/(loss) 45 (157) (492) (81)
Other comprehensive income/(loss) before allocation to noncontrolling interests 367 (166) (231) (35)
Comprehensive income/(loss) before allocation to noncontrolling interests 3,917 4,307 9,221 7,609
Less: Comprehensive income/(loss) attributable to noncontrolling interests 4 (3) 26 (2)
Comprehensive income/(loss) attributable to Pfizer Inc. $ 3,913 $ 4,310 $ 9,195 $ 7,611
[1] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
[2] Reclassified into Other (income)/deductions—net.